SCHEMBL2255248

SCHEMBL2255248

O=C(O)c1ccc(-c2ccc(F)cc2)cc1CCc1ccc2ccccc2c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SOX18 P35713 1/20 0.50
DCLRE1B Q9H816 2/20 0.48
DCLRE1A Q6PJP8 1/20 0.48
ACMSD Q8TDX5 1/20 0.45
CYP1A2 P05177 1/20 0.45
HCAR2 Q8TDS4 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
BCL2L1 Q07817 1/20 0.43
BAD Q92934 1/20 0.43
RARB P10826 2/20 0.41
RARA P10276 1/20 0.41
RARG P13631 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
ANO1 Q5XXA6 1/20 0.41
PTGES O14684 1/20 0.40
ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2252452 0.90 BCL2L1 (0.46) DCLRE1BDCLRE1AHCAR2BCL2L1BAD
SCHEMBL2254854 0.89 EGFR (0.47) SOX18DCLRE1BDCLRE1AHCAR2RARB
SCHEMBL2250853 0.88 DCLRE1B (0.54) DCLRE1BDCLRE1AACMSDHCAR2BCL2L1
SCHEMBL2251799 0.88 DCLRE1B (0.57) DCLRE1BDCLRE1AACMSDHCAR2BCL2L1
SCHEMBL2258585 0.87 PTPN1 (0.47) SOX18DCLRE1BDCLRE1AHCAR2BCL2L1
SCHEMBL2254822 0.86 DCLRE1B (0.56) DCLRE1BDCLRE1AACMSDHCAR2BCL2L1
SCHEMBL2257615 0.85 SOX18 (0.46) SOX18DCLRE1BDCLRE1AACMSDHCAR2
SCHEMBL2251911 0.84 NR1H4 (0.54) MEN1KMT2A
SCHEMBL2255006 0.82 RARB (0.47) DCLRE1BDCLRE1AHCAR2RARBRARA
SCHEMBL2255122 0.82 RARB (0.44) DCLRE1BDCLRE1AHCAR2RARBRARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904047-B1 APOPTOSIS PROMOTERS ABBOTT LAB (US) 2013-01-02 EP disclosed
US-7989656-B2 Biaryl carboxylic acid apoptosis promoters ABBOTT LABORATORIES (US) 2011-08-02 US disclosed
US-20100234456-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2010-09-16 US disclosed
US-7750004-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-06 US disclosed
EP-1904047-A2 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2008-04-02 EP disclosed
US-20070135392-A1 Apoptosis promoters ABBVIE INC. 2007-06-14 US disclosed
WO-2007008627-A2 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234456-A1 APOPTOSIS PROMOTERS MCL1, BAX, BCL2 SOX18 1183/4885DCLRE1B 129/4885DCLRE1A 270/4885
US-20070135392-A1 Apoptosis promoters MCL1, BAX, BCL2 SOX18 1183/4885DCLRE1B 129/4885DCLRE1A 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.